Cardiovascular Organ Damage and Blood Pressure Levels Predict Adverse Events in Multiple Myeloma Patients Undergoing Carfilzomib Therapy

Carfilzomib is a second-generation proteasome inhibitor approved for the treatment of multiple myeloma (MM). It seems to determine cardiovascular toxicity, primarily arterial hypertension. No predictive factors for cardiovascular adverse events (CVAEs) are known in patients affected by multiple myel...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Bruno, Giulia, Bringhen, Sara, Maffei, Ilaria, Iannaccone, Andrea, Crea, Teresa, Ravera, Agnese, Astarita, Anna, Vallelonga, Fabrizio, Salvini, Marco, Gay, Francesca, Veglio, Franco, Milan, Alberto
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6562621/
https://ncbi.nlm.nih.gov/pubmed/31058856
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11050622
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados